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Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibros-
ing interstitial pneumonia of unknown cause, and the prognosis remains poor. On the other
hand, other fibrotic interstitial pneumonias such as idiopathic nonspecific interstitial pneu-
monia (I-NSIP) and collagen vascular disease-associated interstitial pneumonia (CVD-IP)
resemble IPF, but they respond to therapy and the prognosis is better. We searched for
biomarkers to distinguish IPF from other fibrotic interstitial pneumonias and investigated
whether S100A9 could be useful for discriminating types of fibrotic interstitial pneumonia
based on our preliminary proteomic findings.
Methods: We measured S100A9 levels in serum and bronchoalveolar lavage fluid (BALF) from 28
patients with IPF, 15 with I-NSIP, 20 with cryptogenic organizing pneumonia (COP), 35 with
CVD-IP and 23 healthy individuals (controls) using enzyme-linked immunosorbent assays.
S100A9 in the lung was also immunohistochemically localized.
Results: S100A9 levels in BALF, but not in serum, were significantly elevated in patients with
IPF compared with I-NSIP, COP, CVD-IP and healthy individuals. S100A9 immunoreactivity
was localized mainly in macrophages and neutrophils in lung specimens from patients with
IPF. The results of receiver operating characteristic (ROC) curve analysis showed that BALF
S100A9 levels had sufficient specificity and sensitivity to distinguish IPF from I-NSIP and CVD-IP.8197273; fax: þ81 958497285.
ki-u.ac.jp (N. Sakamoto).
1 Elsevier Ltd. All rights reserved.
572 A. Hara et al.Conclusion: S100A9 in BALF might serve as a candidate biomarker to discriminate between IPF
and other fibrotic interstitial pneumonias.
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Idiopathic pulmonary fibrosis (IPF) is the most prevalent
form of idiopathic interstitial pneumonias (IIPs). It is
defined as a specific form of chronic, progressive fibrosing
interstitial pneumonia of unknown cause that occurs
primarily in older adults and it is limited to the lungs.1
Although recent clinical trials of some agents have sug-
gested a benefit for IPF, medical therapy has not enhanced
survival and the prognosis remains poor. The major forms of
IIPs are cryptogenic organizing pneumonia (COP) and
nonspecific interstitial pneumonia (NSIP) that is pathologi-
cally characterized by varying degrees of inflammation and
fibrosis and it clinically mimics IPF.2,3 In addition, collagen
vascular disease (CVD) is often accompanied by fibrotic
interstitial pneumonia that resembles IPF and idiopathic
NSIP (I-NSIP). Thus, to clinically distinguish IPF from I-NSIP
and interstitial pneumonia associated with CVD (CVD-IP) is
often difficult. However, the prognosis is better for I-NSIP
and CVD-IP than for IPF, and patients also respond well to
immunosuppressive therapy.4e7 Therefore, to differentiate
between IPF and other fibrotic interstitial pneumonias such
as I-NSIP and CVD-IP is important.2,3,8 High-resolution
computed tomography (HRCT) is considered useful for dis-
tinguishing I-NSIP and CVD-IP from IPF.9e11 However,
patients with IPF often have atypical CT features that
preclude a definitive diagnosis even when using HRCT. On
the other hand, the value of histological findings that were
once considered the diagnostic gold standard is in fact
limited by sampling bias, interobserver variation and the
risk of acute exacerbation.3 Therefore, biomarkers are
needed to predict the activity, prognosis and etiology of IPF
and distinguish it from other fibrotic interstitial pneumonias
such as I-NSIP and CVD-IP. Based on this background, pro-
teomic studies of interstitial lung disease have detected
several proteins that are differentially expressed in
patients with IPF.
Calcium-binding S100 proteins comprise a family of over
20 members that is characterized by two calcium binding
EF-hand motifs connected by a central hinge region.12
Among them, S100A8 (also named calgranulin A; myeloid-
related protein 8, MRP8), and S100A9 (calgranulin B;
MRP14) are expressed in granulocytes, monocytes and
macrophages at early differentiation stages, and they can
be induced in keratinocytes and epithelial cells under
inflammatory conditions.12 S100A8 and S100A9 generally
regulate gene expression in parallel, and the preferred
form for human S100A8 and S100A9 is the S100A8/S100A9
heterodimer. The S100A8/S100A9 complex has proven
useful as a diagnostic marker of inflammation especially in
non-infectious inflammatory diseases. S100A8 and S100A9
also form homodimers, and differential S100A8 and S100A9
expression indicates chronic inflammation.13 Proteomics
studies14e16 and sandwich enzyme-linked immunosorbentassays (ELISA)17,18 have shown upregulated and elevated
S100A9 protein levels, respectively, in bronchoalveolar
lavage fluid (BALF) from patients with IPF, and that these
activities are associated with clinical parameters. With
respect to CVD-IP, levels of S100A9 are significantly lower
in BALF from patients with pulmonary fibrosis associated
with systemic sclerosis than with IPF.16 These findings
suggest that S100A9 could be a useful marker of IPF and
play a pivotal role in its pathogenesis. However, S100A9
levels have not been compared among IIPs or in patients
with CVD-IP other than systemic sclerosis, and serum
S100A9 levels have not been measured in patients
with IIPs.
The present study measures serum and BALF levels of
S100A9 in IIPs and CVD-IP and determines associations
between these values and the clinical features of IPF.Materials and methods
Study population
We enrolled 28 patients (23 males and 5 females; age,
63.2 10.2 years; mean SD) with IPF, 15 (8 males and 7
females; age, 56.7 13.0 years) with I-NSIP, 20 (12 males
and 8 females; age, 67.0 12.9 years) with COP, 35 (11
males and 24 females; age, 62.2 11.8 years) with CVD-IP
and 23 healthy volunteers (17 males and 6 females; age,
28.0 8.6 years) from Nagasaki University Hospital
between 1992 and 2010. The IIPs were diagnosed according
to the consensus criteria of the American Thoracic Society/
European Respiratory Society.19 The associated diagnoses in
the patients with CVD-IP were rheumatoid arthritis (RA;
nZ 8), polymyositis (PM)/dermatomyositis (DM) (nZ 7),
Sjo¨gren’s syndrome (SjS) (nZ 6), systemic sclerosis (SSc;
nZ 12), PMþ RA (nZ 1) and SScþ DM (nZ 1).
Of these, 41 (IPF, nZ 16; I-NSIP, nZ 15, CVD-IP,
nZ 10) were pathologically confirmed by analyzing
surgical lung biopsy specimens obtained from at least two
sites. All patients with NSIP were pathologically diagnosed
with fibrotic NSIP. Patients with CVD-IP were pathologi-
cally diagnosed with usual interstitial pneumonia (UIP) or
fibrotic NSIP. Other patients with CVD-IP that were not
confirmed by surgical lung biopsy were clinically diagnosed
based on HRCT and BALF findings of fibrotic interstitial
pneumonia. Among patients with CVD, those with orga-
nizing pneumonia, airway involvement and infections were
excluded. None of the included patients had received
steroids or other immunosuppressive therapy at the time
of sample collection. Data from pulmonary function tests,
arterial blood gas analyses, markers of interstitial pneu-
monia including lactic dehydrogenase (LDH), Krebs von
den Lungen 6 (KL-6), surfactant proteins (SP)-A and SP-D,
and survival rates were obtained from medical records.
S100A9 in IPF 573Patients with cancer were excluded. All healthy volun-
teers had normal chest radiographs, were asymptomatic
and not under any medication. The Human Ethics Review
Committee of Nagasaki University School of Medicine
approved the study protocol and all participants provided
written, informed consent prior to enrollment in the
study.
Bronchoalveolar lavage and cell preparation
Bronchoscopy and bronchoalveolar lavage proceeded as
described.20 Three instillations of sterile physiological
saline (50 mL) were delivered at body temperature through
a bronchoscope (BF P200, Olympus, Tokyo, Japan). Lavage
fluid was immediately retrieved by gentle suction using
a sterile syringe, passed through two sheets of gauze, and
then the supernatant separated by centrifugation at
400 g for 10 min at 4 C was stored at 80 C. Sedimented
cells were washed twice with phosphate buffered saline
(PBS), suspended in 10% heat-inactivated fetal calf serum
(FCS) and counted using a hemocytometer. A portion was
then adjusted to 2 105 cells/mL and 0.2 mL of each cell
suspension was sedimented by cytocentrifugation (Cytospin
3, Shandon Instruments, Sewickley, PA, USA) onto glass
slides at 160 g for 2 min. The slides were dried, fixed, and
then the morphology of 200 cells stained with May-Giemsa
was visualized by photomicroscopy. The remaining cells
were resuspended in RPMI-1640 medium (Gibco, Paisley,
Scotland, UK) supplemented with 10% FCS and incubated in
plastic dishes for 60 min at 37 C in a humidified 5% CO2-air
environment. Trypan blue exclusion showed that the
viability of the non-adherent cells collected for flow
cytometry was >90%. The borderline of cells stained or
unstained with phycoerythrin (PE)-conjugated CD4 and CD8
antibodies was determined by flow cytometry using mouse
IgG1 and IgG2a conjugated with FITC or PE (Becton Dick-
inson, San Jose, CA, USA).
Protein extraction and two-dimensional gel
electrophoresis
The protein concentration in BAL samples from five patients
with IPF and from healthy individuals (controls) was
determined using a Protein Assay kit (Bio-Rad Japan, Tokyo,
Japan). Albumin and IgG from BAL samples containing
100 mg of protein were removed using ProteoPrep Blue
Albumin and an IgG Depletion kit according to the manu-
facturer’s protocol (Sigma, St. Louis, MO, USA). Five
samples from patients with the same disease were mixed
and precipitated in acetone at 30 C for 2 h and then the
precipitated proteins were collected by centrifugation at
20,000 g for 20 min. The acetone was discarded and the
pellet was dried for a few minutes at room temperature.
The protein precipitate was resuspended in 250 mL of
isoelectric focusing (IEF) lysis buffer (6 M urea, 2 M thio-
urea), 3% 3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulphonate, 1% Triton X-100 and DeStreak reagent
(GE Healthcare Biosciences, Tokyo, Japan), gently vortex-
mixed for 45 min at room temperature and then the
lysate was separated by centrifugation at 20,000 g for
15 min.Samples were rehydrated in Immobiline DryStrip gels (pH
3e10 non-linear, 13 cm; GE Healthcare Biosciences) for 12 h
and then equilibrated in strip equilibration buffer [6 M
urea, 20% glycerol, 2% dithiothreitol (DTT), 2% sodium
dodecyl sulfate and 375 mM TriseHCl pH 8$8] for 45 min
before being isoelectrically focused at 150 V for 1 h, 5000 V
ramping for 2.5 h and IEF at 5000 V for 15 h. Two-
dimensional gel electrophoresis (2DE) proceeded as
described21 at a constant current of 25 mA for w4 h
(10e18% polyacrylamide gradient gel; 16 16 cm). Gels
were placed in SYPRO Ruby Protein Gel Stain (Bio-Rad,
Hercules, CA, USA) for 16 h and then destained in 10%
methanol and 7% acetic acid. Images were acquired using
a MOLECULAR IMAGER FX (Bio-Rad) and the images were
exported to the image analysis software program, PDQuest
(Bio-Rad).
Mass spectrometry and database analysis
Spots from SYPRO Ruby Protein Gel Stain 2D gels were
excised, reduced in-gel, alkylated, trypsinized and
analyzed by liquid chromatography-mass spectrometry (LC-
MS) using a DiNa-2A nanoLC system (KYA Technologies,
Tokyo, Japan) coupled online to a LCMS-IT-TOF mass spec-
trometer (Shimadzu, Kyoto, Japan). The LC separation
proceeded using a PicoFrit column BetaBasic C18 (New
Objective, Woburn, MA, USA) at a constant flow rate of
300 nL/min. Peptides were eluted from 10 mL samples using
gradients of 5e40% solvent B (0.1% formic acid in 80% ACN)/
0e30 min, 40e100% solvent B/30e40 min, and 100e100%
solvent B/40e60 min. LCMS-IT-TOF was operated in the
data-dependent MS/MS mode. The capillary temperature
and electrospray voltage were set at 200 C and 2.2 kV,
respectively. Data were collected at scan ranges of
400e1500 for MS and 50e1500 for MS/MS. Proteins were
identified by Mascot searches (Matrix Science, http://www.
matrixscience.com/).
Measurement of S100A9 by ELISA
Serum and BALF concentrations of S100A9 were measured
using a sandwich enzyme-linked immunosorbent assay
(ELISA) kit (BMA Biomedicals, Augst, Switzerland) according
to the manufacturer’s protocols. The lower limit of detec-
tion was 0.31 ng/mL. Albumin concentrations in BALF were
determined by a Human Albumin ELISA Quantitation Kit
(Bethyl Laboratories, Montgomety, TX, USA).
Immunohistochemical staining
Specimens were immunohistochemically analyzed by
conventional avidin-biotin-peroxidase staining using the
Vectastain Elite ABC kit (Vector Laboratories, Burlingame,
CA, USA). Briefly, sequential 4-mm paraffin sections were
deparaffinized with toluene and rinsed thoroughly with
absolute ethanol. Antigen was retrieved by incubating
sections with proteinase K for 15 min. The sections were
soaked in absolute methanol containing 0.3% H2O2 with for
20 min at room temperature to inactivate endogenous
peroxidase and then incubated with serum for 20 min fol-
lowed by a mouse anti-human S100A9 monoclonal antibody
Table 1 Characteristics of patients with IPF, I-NSIP, COP and CVD-IP.
IPF (NZ 28) I-NSIP (NZ 15) COP (NZ 20) CVD-IP (NZ 35)
Age (years) 63.2 10.2 56.7 13.0 67.0 12.9 62.2 11.8
Gender (M/F) 23/5 8/7 12/8 11/24
Pulmonary function tests
%VC (%) 82.8 20.1 78.6 18.5 96.2 16.5 84.7 23.1
FEV1.0% (%) 81.2 7.9 78.8 12.2 75.5 13.0 83.0 12.1
%DLCO (%) 50.7 14.8 61.5 21.9 67.6 23.9 56.5 15.3
Laboratory data
CRP (mg/dL) 0.46 0.49 0.47 0.40 3.43 4.34*,y 1.30 3.00
LDH (IU/L) 300 127 228 94 190 36* 288 166
KL-6 (U/mL) 1448 1020 1281 777 512 343* 1083 704
SP-A (ng/mL) 120 62 69 63 68 34 83 48
SP-D (ng/mL) 297 175 410 242 194 157y 184 86y
PaO2 (Torr) 81.0 12.0 82.6 6.5 77.5 11.2 81.7 9.4
%DLCO, ratio of diffusing capacity for carbon monoxide; CRP, C-reactive protein; LDH, lactic dehydrogenase; KL-6, Krebs von den Lungen
6; SP-A, surfactant protein A; SP-D, surfactant protein D; Data are means SD. *p< 0.05 vs. IPF; yp< 0.05 vs. I-NSIP.
574 A. Hara et al.overnight at 4 C (BMA Biomedicals). The sections were
washed in PBS, processed according to the manufacturer’s
instructions provided with the kits, developed with 3,30-
diaminobenzidine and H2O2 and then stained with Mayer’s
hematoxylin. Control lung tissues were obtained from
normal areas of lungs that were surgically removed to treat
cancer. Negative control studies included non-immunized
immunoglobulin G with the same subclass of first antibody
instead of primary antibody.
Statistical analysis
All values are expressed as means SD. Differences
between multiple groups were compared using the Krus-
kaleWallis test and the post hoc Scheffe´ test. Correlations
between parameters were determined by Pearson’s corre-
lation coefficient. Survival data were analyzed using
KaplaneMeier curves and survival between two groups was
compared using the log-rank test. The concentrations of
serum S100A9, KL-6, SP-D and SP-A, and of S100A9 in BALF
were analyzed using receiver operating characteristic
(ROC) curves to determine cut-off values for optimal
discriminative accuracy. p Values of <0.05 were regarded
as significant. Data without ROC curves were analyzed using
statistical software (Stat ViewJ-5.0. SAS Institute, Cary, NC,
USA) and ROC curves were analyzed using Ekuseru-Toukei
2010 (Social Survey Research Information Co. Ltd., Tokyo,
Japan).Table 2 Cell findings in BALF from patients with IPF, I-NSIP, CO
IPF (NZ 28) I-NSIP (NZ
TCC (105/mL) 4.1 1.5 3.5 1.2
Macrophages (%) 70.7 15.4 53.2 19.
Lymphocytes (%) 16.5 12.9 41.3 19.
Neutrophils (%) 6.5 6.6 2.8 2.9
Eosinophils (%) 6.1 7.2 2.5 2.6
CD4/CD8 1.5 1.1 1.9 5.7
TCC, total cell count; Data are means SD. *p< 0.05 vs. IPF, yp< 0.0Results
Characteristics of study population
Table 1 shows the characteristics of the patients with IPF,
I-NSIP, COP and CVD-IP. Serum concentrations of C-reactive
protein (CRP) in patients with COP were increased
compared with IPF and I-NSIP (p< 0.05), and those of KL-6
and LDH in patients with IPF were higher than those with
COP (p< 0.05). Serum SP-D levels in patients with I-NSIP
were higher than in those with COP and CVD-IP (p< 0.05).
Table 2 shows the components of BALF from patients with
IPF, I-NSIP, COP and CVD-IP. The ratio of lymphocytes was
significantly higher in patients with I-NSIP and COP than
with IPF (p< 0.05) and that of neutrophils was higher in
patients with CVD-IP than with I-NSIP (p< 0.05).Two-dimensional gel electrophoresis of BALF
We analyzed protein profiles in BALF from healthy controls
and from patients with IPF (Fig. 1a and b, respectively).
Among a total of 170 and 206 respectively resolved protein
spots, one was selected for differential expression analysis
based on at least a fivefold increase in the optical density in
samples from patients with IPF compared with values from
controls. Mass spectrometry and Mascot searches revealed
that the intense spot in BALF from IPF patients was S100A9.P and CVD-IP.
15) COP (NZ 20) CVD-IP (NZ 35)
5.7 3.5 4.0 2.4
7 44.9 25.2* 55.2 20.3*
4* 44.9 26.3* 29.2 21.6
6.6 6.4 10.4 11.3y
3.4 4.4 3.9 4.5
1.5 1.4 1.2 1.5
5 vs. I-NSIP.
Figure 1 Analytical two-dimensional gel electrophoresis of BALF from healthy control (a) and IPF (b). Non-linear 10e18% gradient
gels (pH 3$0e10$0) were stained with SYPRO Ruby Protein Gel Stain. Spot indicated by arrow is more intense in (b) than in (a).
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We quantified S100A9 levels in serum and BALF from
healthy controls and from patients with IPF, I-NSIP, COP
and CVD-IP using an ELISA. Serum levels of S100A9
(Fig. 2a) in IPF patients tended to be higher than in
patients with I-NSIP, COP and in controls, but theFigure 2 Serum (a) and BALF (b) levels of S100A9. Levels of S100A
CVD-IP and healthy controls. *p< 0.05 compared with IPF.difference did not reach statistical significance. Levels of
S100A9 in BALF (Fig. 2b) were higher in patients with IPF
than with I-NSIP, COP and CVD-IP, and in controls
(p< 0.05). BALF S100A9 levels normalized for albumin
levels in BALF showed similar results including ROC curve
analysis and association with clinical parameters (data
not shown).9 in BALF are higher in patients with IPF than with I-NSIP, COP,
Table 3 Correlation between S100A9 and clinical param-
eters in patients with IPF.
Variable Serum S100A9 BALF S100A9
r p Value r p Value
Age 0.24 0.22 0.03 0.87
CRP 0.06 0.77 0.11 0.59
LDH 0.19 0.33 0.15 0.44
KL-6 0.03 0.89 0.41 0.03
SP-A 0.04 0.85 0.08 0.72
SP-D 0.15 0.49 0.28 0.19
%VC 0.14 0.47 0.13 0.53
FEV1.0% 0.07 0.71 0.03 0.87
%DLCO 0.06 0.77 0.04 0.82
BALF cell findings
TCC (105/mL) 0.19 0.34 0.003 0.98
Macrophages (%) 0.003 0.98 0.09 0.67
Lymphocytes (%) 0.12 0.53 0.27 0.16
Neutrophils (%) 0.33 0.08 0.64 <0.01
Neutrophils (105/mL) 0.54 <0.01 0.49 <0.01
Eosinophils (%) 0.08 0.68 0.04 0.82
CD4/CD8 0.16 0.41 0.03 0.88
576 A. Hara et al.ROC for biomarkers of IPF versus other fibrotic
interstitial pneumonias
We evaluated the sensitivity and specificity of distinguish-
ing IPF from I-NSIP and CVD-IP based on BALF S100A9 levels
using ROC curves, because the levels were significantly
elevated in patients with IPF compared with those who had
I-NSIP and CVD-IP, and thus, might serve as a useful marker
of IPF. Fig. 3 shows the ROC curves for S100A9 obtained
from serum and BALF and for markers of interstitial lung
disease (KL-6, SP-D and SP-A) in patients with IPF and other
fibrotic interstitial pneumonias (I-NSIP and CVD-IP). The
area under the ROC curve (AUC) was the largest for S100A9
in BALF; serum S100A9, 0.773; BALF S100A9, 0.972; KL-6,
0.571; SP-D, 0.684; SP-A, 0.726. Cut-off values taken as
the points closest to 100% sensitivity and 100% specificity,
were 4.95 and 1 ng/mL for serum (sensitivity, 96.4%;
specificity, 57.8%) and BALF (sensitivity, 96.4%; specificity,
87.8%) S100A9, respectively. Levels of S100A9 in BALF were
more specific and sensitive than other markers of intersti-
tial pneumonia in terms of distinguishing IPF from other
fibrotic interstitial pneumonias.CRP, C-reactive protein; LDH, lactic dehydrogenase; KL-6, Krebs
von den Lungen 6; SP-A, surfactant protein A; SP-D, surfactant
protein D; %DLCO, ratio of diffusing capacity for carbon
monoxide; TCC, total cell count.Association between S100A9 and clinical
parameters in patients with IPF
We analyzed the relationship between the clinical param-
eters of pulmonary function, arterial blood gases, markers
of interstitial lung diseases and BALF cell findings, and
levels of S100A9 in patients to determine the role of S100A9
in IPF (Table 3). Levels of S100A9 in both serum and BALF
from all study participants did not significantly correlate
(rZ 0.12, pZ 0.25). Serum and BALF levels of S100A9 did
not significantly correlate with pulmonary function, partial
pressure of oxygen, or serum levels of CRP, LDH, SP-D and
SP-A. Higher levels of BALF S100A9 were associated with
lower serum levels of KL-6 (rZ0.41, pZ 0.03). SerumFigure 3 Receiver operating characteristic (ROC) curves for
biomarkers of IPF versus I-NSIP and CVD-IP. Area under ROC
curve: serum S100A9, 0.773; BALF S100A9, 0.972; KL-6, 0.571;
SP-D, 0.684; SP-A 0.726.and BALF levels of S100A9 significantly correlated with the
number of neutrophils in BALF (Table 3, Fig. 4) and did not
correlated with survival rates for patients with IPF (data
not shown). The results were similar even when the data
was analyzed in patients with biopsy proven IPF (data not
shown).
Immunohistochemical staining of S100A9
Fig. 5 shows representative lung specimens that were
immunohistochemically stained for S100A9 and obtained
from normal areas of lungs surgically removed to treat
cancer and from patients with IPF and I-NSIP. S100A9 was
expressed weakly in control lung specimens (Fig. 5a) but
obviously and mainly in macrophages in the airspace and
in inflammatory cells that were supposedly macrophages
and neutrophils in lung specimens from patients with IPF
(Fig. 5bed). S100A9 was also overexpressed in endothelial
vascular cells (Fig. 5e), weakly expressed in alveolar
epithelial cells and absent in fibroblasts. Although S100A9
immunoreactivity did not significantly differ between IPF
and I-NSIP, lymphocytes did not overexpress S100A9 in
lung specimens from patients with I-NSIP (Fig. 5f). S100A9
immunoreactivity in CVD-IP patients did not differ
between IPF and CVD-IP (data not shown).
Discussion
The IIPs are an important subset of a broader category of
interstitial lung diseases.19 Among these, IPF and I-NSIP
have provoked the most debate and discussion because
they are clinically similar, but the outcome of the latter is
Figure 4 Correlation between serum or BALF levels of S100A9 and number of neutrophils in BALF of patients with IPF. Serum and
BALF levels of S100A9 significantly correlate with number of neutrophils in BALF (serum: rZ 0.54, p< 0.01; BALF, rZ 0.49,
p< 0.01).
S100A9 in IPF 577far more favorable.2,3 The potential of several proteins,
such as KL-6, SP-A and SP-D, as biomarkers of interstitial
lung disease has been examined in the clinical setting.
However, no biomarkers can yet distinguish IPF from I-NSIP.
In addition, CVD is accompanied by fibrotic interstitial
pneumonia that resembles IPF and I-NSIP. Some patients
with CVD do not have typical symptoms other than inter-
stitial pneumonia. Thus, to distinguish IPF from I-NSIP and
CVD-IP is often difficult. The present study found elevated
levels of S100A9 in BALF from patients with IPF compared
with other types of IIPs, CVD-IP and from healthy controls.
Furthermore, ROC curve analyses showed that BALF S100A9
levels could distinguish IPF from I-NSIP and CVD-IP with
higher specificity and sensitivity than other markers of
interstitial pneumonia. This suggests that S100A9 in BALF
could serve as a novel biomarker, especially in terms of
distinguishing IPF from I-NSIP and CVD-IP. Furthermore,
others have found that S100A9 levels in BALF are increased
compared with sarcoidosis,16,18 suggesting that high S100A9
expression in BALF is specific to IPF.
Serum S100A9 levels in the present study were increased
not only in patients with IPF, but also in those with CVD-IP.
S100A9 in serum is overexpressed under inflammatory
conditions such as chronic inflammatory bowel diseases,
Kawasaki disease and collagen vascular diseases (rheuma-
toid arthritis, systemic lupus erythematosus, Sjo¨gren’s
syndrome, systemic sclerosis, dermatomyositis and poly-
myositis).22e26 Even patients with CVD-IP and increased
levels of S100A9 in serum did not have such an increase in
BALF. These results suggest that S100A9 in serum reflects
systemic inflammation, whereas S100A9 in BALF reflects
local inflammatory conditions in the lung. As a result,
S100A9 in BALF, and not in serum, might serve as a marker
to distinguish IPF from I-NSIP and CVD-IP.
Both serum and BALF levels of S100A9 in patients with
IPF were associated with the number of neutrophils in BALF,
which supports previous findings.17,18 S100A9 causes
neutrophil chemotaxins27,28 and neutralization with anti-
bodies against S100A9 blocks neutrophil recruitment.29
Increased levels of S100A9 in BALF might result inneutrophil accumulation in the lungs of patients with IPF.
Neutrophilia frequently appears in BALF from patients with
IPF19,30 and is associated with the clinical features of IPF
and the early mortality of such patients.30,31 Sustained
neutrophil accumulation in the alveolar space and
neutrophil-mediated injury to the alveolar wall are
believed to play a role in interstitial fibrosis and abnormal
lung repair.30 Furthermore, S100A9 reportedly stimulates
the proliferation of fibroblasts that play a pivotal role in
lung fibrosis.32 In contrast, S100A9 participates in wound-
healing,33 protects against bacterial infection34 and oxida-
tive damage,35 and exerts anti-asthmatic effects.36 Thus,
S100A9 is considered to have anti-inflammatory roles and to
mediate host protection.13 Although further studies are
required to elucidate the role of S100A9 in pulmonary
fibrosis, the present results suggest that S100A9 is involved
in the pathogenesis of IPF via neutrophilic inflammation
in IPF.
The immunohistochemical findings revealed S100A9
expression mainly in macrophages in the air space, in
interstitial inflammatory cells such as macrophages and
neutrophils, and in endothelial vascular cells of the lungs
from patients with IPF.17 Interstitial inflammatory cells in
the lungs of patients with I-NSIP and CVD-IP express similar
amounts of S100A9, whereas the S100A9 levels in BALF
differed between IPF and others. S100A9 is now considered
as a damage-associated molecular pattern protein (DAMP),
because it exists in an intracellular form that is released by
activated or damaged cells under conditions of cellular
stress.12 S100A9 is secreted by neutrophils during interac-
tions with endothelial cells, suggesting that it plays a role in
leukocyte migration.37 In addition, S100A9 secretion is
induced in neutrophils by factors such as lipopolysaccharide
and C5a,13 as well as in monocytes by PMA.38 Necrotic
neutrophils also release S100A9.39 Although the reason for
the discrepancy between BALF levels and immunohisto-
chemical expression of S100A9 remains unclear, different
mechanisms might be involved such as the release, clear-
ance or degradation of S100A9 in the lungs of patients with
IPF compared with other fibrotic interstitial pneumonias.
Figure 5 Immunohistochemical staining of S100A9 in lung specimens from control (a) and patients with IPF (bee) and I-NSIP (f).
(a) Control lung specimens (normal areas of lungs surgically removed for lung cancer) (40) (b) Expression of S100A9 in lung
specimens from patients with IPF (40) (c) S100A9 expressed by macrophages (200). (d) S100A9 expressed by inflammatory cells
that are supposedly macrophages and neutrophils (200). (e) S100A9 overexpression by endothelial vascular cells (100) (f)
Expression of S100A9 in lung specimens from patients with I-NSIP (40). Scale barsZ 200 (a, b, f) and 100 (cee) mm.
578 A. Hara et al.The present study did not identify an association
between S100A9 levels and other clinical parameters such
as lung function, arterial blood gases and prognosis in IPF
patients. Korthagen et al. reported a similar lack of asso-
ciation between BALF S100A9 levels and lung functions.18
On the other hand, Bargagli et al. reported that BALF
S100A9 levels normalized for BALF total protein concen-
trations inversely correlate with lung function.17 Further
studies are required to clarify the role of S100A9 from
clinical aspects and the pathogenesis of IPF.
In conclusion, this study demonstrated higher BALF
levels of S100A9 in patients with IPF than in those with
I-NSIP, COP and CVD-IP and in healthy controls. S100A9 in
BALF might be a useful candidate biomarker with which to
discriminate IPF from other fibrotic interstitial pneumonias
such as I-NSIP and CVD-IP.Conflict of interest statement
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